vida: extract claims from 2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure

- Source: inbox/queue/2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -74,3 +74,10 @@ First RCT evidence: 26-week trial of 108 AUD+obesity patients showed semaglutide
 **Source:** Clinical Trial Vanguard 2026-04-01
 
 Concurrent psychotropic medication use (antidepressants, benzodiazepines) shows OR 4.07-4.45 for suicidality in GLP-1 users, suggesting the dopaminergic mechanism may interact adversely with psychiatric medications rather than uniformly benefiting substance use disorder patients. The protective AUD signal may be specific to metabolic disease + AUD comorbidity rather than primary psychiatric AUD.
+
+
+## Extending Evidence
+
+**Source:** The Lancet 2026, EVOKE/EVOKE+ Phase 3 failure
+
+EVOKE/EVOKE+ Alzheimer's failure provides critical boundary evidence for GLP-1 CNS mechanism specificity. Semaglutide succeeds in addiction (VTA dopamine reward circuits) but fails in neurodegeneration (amyloid/tau pathways), demonstrating that GLP-1 receptor activation produces pathway-specific effects rather than broad neuroprotection. This supports the mesolimbic dopamine mechanism for addiction while ruling out generalized CNS benefit claims.

entities/health/evoke-evoke-plus-trials.md

@@ -0,0 +1,50 @@
+# EVOKE/EVOKE+ Trials
+
+**Type:** Phase 3 clinical trials  
+**Sponsor:** Novo Nordisk  
+**Intervention:** Oral semaglutide 14mg (flexible dose)  
+**Indication:** Early-stage symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia with confirmed amyloid positivity)  
+**Status:** Failed (2026)  
+
+## Trial Design
+
+- **Design:** Two parallel Phase 3, double-blind, placebo-controlled trials
+- **Population:** n=3,808 total, ages 55-85
+- **Duration:** 104 weeks primary endpoint, 156 weeks extended follow-up
+- **Primary endpoints:** Cognitive and global decline measures
+
+## Results
+
+**Primary endpoints:** Not met in either trial. Semaglutide did not demonstrate superiority to placebo in slowing cognitive or global decline.
+
+**Secondary endpoints:**
+- No delay in time to progression to dementia (MCI subgroup, pooled analysis)
+- **Biomarker findings:** Up to 10% reduction in CSF core AD biomarkers (amyloid, tau)
+- Significant reductions in CSF neuroinflammation markers
+- **Critical gap:** Biomarker improvements did not translate to clinical benefit
+
+## Scientific Interpretation
+
+The biomarker-clinical benefit dissociation suggests three possible explanations:
+1. Dose insufficient to produce clinical effect despite biomarker change
+2. Treatment window too late (early symptomatic disease already past intervention point)
+3. Neuroinflammation/AD pathobiology not rate-limiting in this population
+
+## Implications
+
+**For GLP-1 CNS expansion:** Establishes mechanism specificity boundary. Semaglutide shows efficacy in addiction (VTA dopamine pathways) but not neurodegeneration (amyloid/tau pathways), indicating GLP-1 CNS effects are pathway-specific rather than universally neuroprotective.
+
+**For Alzheimer's drug development:** Adds to evidence that biomarker improvement (even in core AD pathology markers) does not guarantee clinical benefit, raising questions about surrogate endpoint validity.
+
+**For prevention vs. treatment:** May indicate GLP-1 has preventive rather than therapeutic value in neurodegeneration, requiring different trial design in at-risk populations.
+
+## Timeline
+
+- **2026-04-15** — Results published in The Lancet
+- **2026-04** — Novo Nordisk announces discontinuation of 1-year extension periods for both trials
+
+## Sources
+
+- The Lancet (2026): "Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials"
+- Alzheimer's Drug Discovery Foundation analysis
+- NeurologyLive coverage

inbox/archive/health/2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure.md

@@ -7,10 +7,13 @@ date: 2026-04-15
 domain: health
 secondary_domains: []
 format: research-article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-03
 priority: medium
 tags: [GLP-1, semaglutide, Alzheimers, neurodegeneration, Phase-3, clinical-failure, biomarker-gap, CNS]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content